scholarly journals Promoter haplotypes of interleukin-10 gene linked to cortex plasticity in subjects with risk of Alzheimer's disease

2018 ◽  
Vol 17 ◽  
pp. 587-595 ◽  
Author(s):  
Feng Bai ◽  
Chunming Xie ◽  
Yonggui Yuan ◽  
Yongmei Shi ◽  
Zhijun Zhang
2004 ◽  
Vol 356 (2) ◽  
pp. 119-122 ◽  
Author(s):  
Catia Scassellati ◽  
Roberta Zanardini ◽  
Rosanna Squitti ◽  
Luisella Bocchio-Chiavetto ◽  
Cristian Bonvicini ◽  
...  

2008 ◽  
Vol 115 (6) ◽  
pp. 863-867 ◽  
Author(s):  
O. Combarros ◽  
P. Sánchez-Juan ◽  
J. A. Riancho ◽  
I. Mateo ◽  
E. Rodríguez-Rodríguez ◽  
...  

2020 ◽  
Vol 2020 ◽  
pp. 1-17 ◽  
Author(s):  
Yan-Fang Xian ◽  
Chang Qu ◽  
Yue Liu ◽  
Siu-Po Ip ◽  
Qiu-Ju Yuan ◽  
...  

Alzheimer’s disease (AD) is a common neurodegenerative disease characterized by progressive memory loss. Magnolol (MN), the main active ingredient of Magnolia officinalis, possesses anti-AD effects in several experimental models of AD. In this study, we aimed to explore whether MN could ameliorate the cognitive deficits in TgCRND8 transgenic mice and to elucidate its molecular mechanisms. Male TgCRND8 mice were orally administered with MN (20 and 40 mg/kg) daily for 4 consecutive months, followed by assessing the spatial learning and memory functions using the open-field, radial arm maze, and novel object recognition tests. The results demonstrated that MN (20 and 40 mg/kg) could markedly ameliorate the cognitive deficits in TgCRND8 mice. In addition, MN significantly increased the expression of postsynaptic density protein 93 (PSD93), PSD-95, synapsin-1, synaptotagmin-1, synaptophysin (SYN), and interleukin-10 (IL-10), while markedly reduced the protein levels of tumor necrosis factor alpha (TNF-α), IL-6, IL-1β, Aβ40, and Aβ42, and modulated the amyloid precursor protein (APP) processing and phosphorylation. Immunofluorescence showed that MN significantly suppressed the activation of microglia (Iba-1) and astrocytes (GFAP) in the hippocampus and cerebral cortex of TgCRND8 mice. Mechanistic studies revealed that MN could significantly increase the ratios of p-GSK-3β (Ser9)/GSK-3β, p-Akt (Ser473)/Akt, and p-NF-κB p65/NF-κB p65. These findings indicate that MN exerted cognitive deficits improving effects via suppressing neuroinflammation, amyloid pathology, and synaptic dysfunction through regulating the PI3K/Akt/GSK-3β and NF-κB pathways, suggesting that MN is a promising naturally occurring polyphenol worthy of further developing into a therapeutic agent for AD treatment.


2016 ◽  
Vol 177 ◽  
pp. 47-52 ◽  
Author(s):  
Gilberto Vargas-Alarcón ◽  
Enrique Juárez-Cedillo ◽  
Nancy Martínez-Rodríguez ◽  
José Manuel Fragoso ◽  
Normand García-Hernández ◽  
...  

Brain ◽  
2020 ◽  
Author(s):  
Lisi Flores-Aguilar ◽  
M Florencia Iulita ◽  
Olivia Kovecses ◽  
Maria D Torres ◽  
Sarah M Levi ◽  
...  

Abstract Epidemiological and experimental studies suggest that a disease-aggravating neuroinflammatory process is present at preclinical stages of Alzheimer’s disease. Given that individuals with Down syndrome are at increased genetic risk of Alzheimer’s disease and therefore develop the spectrum of Alzheimer’s neuropathology in a uniform manner, they constitute an important population to study the evolution of neuroinflammation across the Alzheimer’s continuum. Therefore, in this cross-sectional study, we characterized the brain inflammatory profile across the lifespan of individuals with Down syndrome. Microglial morphology and inflammatory cytokine expression were analysed by immunohistochemistry and electrochemiluminescent-based immunoassays in the frontal cortex from foetuses to adults with Down syndrome and control subjects (16 gestational weeks to 64 years), totalling 127 cases. Cytokine expression in mixed foetal primary cultures and hippocampus of adults with Down syndrome, as well as the effects of sex on cytokine expression were also analysed. A higher microglial soma size-to-process length ratio was observed in the frontal cortex of children and young adults with Down syndrome before the development of full-blown Alzheimer’s pathology. Moreover, young adults with Down syndrome also displayed increased numbers of rod-like microglia. Increased levels of interleukin-8 and interleukin-10 were observed in children with Down syndrome (1–10 years; Down syndrome n = 5, controls n = 10) and higher levels of interleukin-1β, interleukin-1α, interleukin-6, interleukin-8, interleukin-10, interleukin-15, eotaxin-3, interferon gamma-induced protein 10, macrophage-derived chemokine, and macrophage inflammatory protein-beta, were found in young adults with Down syndrome compared to euploid cases (13–25 years, Down syndrome n = 6, controls n = 24). Increased cytokine expression was also found in the conditioned media of mixed cortical primary cultures from second trimester foetuses with Down syndrome (Down syndrome n = 7, controls n = 7). Older adults with Down syndrome (39–68 years, Down syndrome n = 22, controls n = 16) displayed reduced levels of interleukin-10, interleukin-12p40, interferon-gamma and tumour necrosis factor-alpha. Microglia displayed larger somas and shorter processes. Moreover, an increase in dystrophic microglia and rod-like microglia aligning to neurons harbouring tau pathology were also observed. Sex stratification analyses revealed that females with Down syndrome had increased interleukin-6 and interleukin-8 levels compared to males with Down syndrome. Finally, multivariate projection methods identified specific cytokine patterns among individuals with Down syndrome. Our findings indicate the presence of an early and evolving neuroinflammatory phenotype across the lifespan in Down syndrome, a knowledge that is relevant for the discovery of stage-specific targets and for the design of possible anti-inflammatory trials against Alzheimer’s disease in this population.


2003 ◽  
Vol 4 (3) ◽  
pp. 234-238 ◽  
Author(s):  
D Lio ◽  
F Licastro ◽  
L Scola ◽  
M Chiappelli ◽  
L M Grimaldi ◽  
...  

2017 ◽  
Vol 75 (9) ◽  
pp. 649-656 ◽  
Author(s):  
Carolina Antunes Magalhães ◽  
Maria das Graças Carvalho ◽  
Lirlândia Pires de Sousa ◽  
Paulo Caramelli ◽  
Karina Braga Gomes

ABSTRACT Alzheimer’s disease (AD) is the most common form of dementia. In the last 15 years, a new theory has proposed the autoimmune mechanism as a trigger for AD. Studies on the association between AD and inflammatory biomarkers have yielded controversial results. Interleukin-10 (IL-10), an anti-inflammatory mediator, has been pointed out as one of the main cytokines associated with the occurrence of AD. Moreover, treatment that increases IL-10 levels could be a potential therapy for AD, since this cytokine acts on amyloid and pro-inflammatory molecule reduction. Based on the current literature, this study reviews evidence regarding the role of IL-10 polymorphisms in the context of AD, which has been shown to be of paramount importance for attenuating neuroinflammation, cognitive dysfunction and neurodegeneration.


Sign in / Sign up

Export Citation Format

Share Document